|
Press Releases |
|
|
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)がイスラエルにおいてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、イスラエルにおいて新薬承認を取得したことをお知らせします。 more info >> |
|
Thursday, July 11, 2024 |
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
エーザイとバイオジェン、「LEQEMBI」(レカネマブ)が香港においてアルツハイマー病治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と バイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、 CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、ヒト化抗ヒト可溶性 アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(香港製品名:「樂意保(R)」、一般名:レカネマブ)について、香港衛生署(Department of Health)より新薬承認を取得したことをお知らせします。 more info >> |
|
Tuesday, July 2, 2024 |
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
Friday, June 28, 2024 |
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
Friday, June 21, 2024 |
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
Monday, June 10, 2024 |
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ(Aβ)凝集体モノクローナル抗体「レケンビ(R)」(一般名:レカネマブ)について、静注(IV)維持投与に関する生物製剤承認一部変更申請(sBLA)が米国食品医薬品局(FDA)に受理されたことをお知らせします。 more info >> |
|
Monday, June 3, 2024 |
|
Eisai Named to List of The Time 100 Most Influential Companies |
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
InfoComm India 2024 Wraps Up with Impressive 17% Increase in Unique Attendance
Sept 9, 2024 23:30 HKT/SGT
|
|
|
Inaugural Hong Kong Shopping Festival ends successfully
Sept 9, 2024 19:03 HKT/SGT
|
|
|
Zhong An Group(0672.HK) Seeks Sustainable Development
Sept 9, 2024 18:43 HKT/SGT
|
|
|
首届「香港好物节」圆满结束
Sept 9, 2024 18:33 HKT/SGT
|
|
|
首屆「香港好物節」圓滿結束
Sept 9, 2024 18:02 HKT/SGT
|
|
|
Kincora Secures New Strategic Ground On Australia's Premier Porphyry Copper-Gold Province
Sept 9, 2024 17:39 HKT/SGT
|
|
|
眾安集團(0672.HK):精耕穩進 扎牢底盤 謀持久發展
Sept 9, 2024 17:38 HKT/SGT
|
|
|
Korea Continues to Lead the Charge in Shaping the Future of Streaming in Asia
Sept 9, 2024 17:37 HKT/SGT
|
|
|
DENSO to Build a New Plant at the Zenmyo Plant
Sept 9, 2024 17:15 JST
|
|
|
三菱重工、H-IIAロケット49号機による情報収集衛星レーダ8号機の打上げ延期について
Sept 9, 2024 16:00: JST
|
|
|
The 44th ASEAN Railway CEOs (ARCEOs') Conference Held in Bandung Achieving Sustainability through Digital Innovation
Sept 9, 2024 15:00 HKT/SGT
|
|
|
Brawijaya University Prof Develops Early Harvest, High-yield Corn Seeds
Sept 9, 2024 12:00 HKT/SGT
|
|
|
アリマンタシォン・クシュタール、セブン&アイ・ホールディングスからの回答に対する声明を発表
Sept 9, 2024 08:00: JST
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME conclude successfully
Sept 8, 2024 15:55 HKT/SGT
|
|
|
香港钟表展及国际名表荟萃圆满结束
Sept 8, 2024 15:45 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|